Clinical trials / NCT02912260
NCT02912260Phase 2Completed

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2017-10-25Actual
Enrollment · participants125Actual
Source updated2025-12-23Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF

+ After

Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)

Primary completion date changed

− Before

Oct 2017

+ After

25 Oct 2017

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source